Joseph Shatzel MD

Dr. Shatzel specializes in caring for adults with bleeding and clotting disorders along with a host of other non-malignant hematologic disorders. His NIH-funded research program focuses on the translational development of novel molecular targets in coagulation, including factors XI and XII, thrombopoietin, and plasminogen. He serves as primary investigator and medical monitor for multiple NIH-funded early-stage clinical trials of novel anticoagulants. His areas of interests include mechanistic insights in contact activation and defining the clinical utility of inhibitors of FXI and FXII for the prevention of medical device-related thrombosis and morbidity in sepsis. He currently serves as the Co-Director of Clinical Research for the department of Biomedical Engineering at the Oregon Health & Science University, and assistant program director the adult hematology fellowship at the Knight Cancer Institute. He has a strong commitment to mentorship and actively mentors and supports multiple trainees.